Antisense Therapeutics Limited (ASX: ANP) ) has announced that it has received a full Options exercise of $5.5 million by conversion and underwriting of listed options that expired on 19 December 2019.
- Antisense thanks all option holders who converted their options and welcomes the support of major shareholders.
- The company also thanked new institutional investors and sophisticated clients of Morgans Corporate Limited (Lead Manager and Underwriter to the Options) who participated in the underwriting.
- The fund raised to be used for phase IIb clinical trial of AT1102 in DMD.
At AEDT (12:53 PM), the stock was trading at $0.0087, down by 2.247 per cent from the previous close.